 |
FERNANDINA BEACH, Florida, May 29, 2026 /PRNewswire/ — Ponce De Leon Health (PDLH), a commercial-grade longevity company focused on extending healthspan and reducing biological age in humans and animals, today published a landmark peer-reviewed study in the scientific journal Aging Cell. Importantly, the study was conducted independently using a large real-world cohort and was not sponsored, directed, or controlled by Ponce De Leon Health.
The authors tested associations between 84 commonly used supplements, drugs, and commercial compounds in an effort to influence the aging process, using the same DNA methylation clock to uniformly determine the biological age of over 4,000 initial subjects. These results were then compared and ranked against each other. In their cross-sectional analysis, only Rejuvant—a commercially available delayed-release CaAKG plus vitamin supplement, which showed an average residual age reduction of 1.8 years as the primary study endpoint—was statistically significant.
In contrast, participants taking regular CaAKG/AKG exhibited an 8-fold weaker effect and were not statistically significant. All forms of NAD+ supplements (such as NMN and NR) showed a 9-fold reduction in effectiveness. Furthermore, all non-Rejuvant cohorts were not statistically significant for this endpoint, and Rejuvant remained significant in models adjusted for age, sex, smoking, health status, and other covariates.
“This is a unique study comparing the effects of 84 different common supplements on actively measuring biological age in a broader healthy population,” said Dr. Brian Kennedy, Director of the Centre for Healthy Longevity at the National University of Singapore and senior author of the paper. “While some supplements showed significance in reducing biological age, by far the largest effect was associated with Rejuvant, where users were 5.74 years younger than their chronological age. After correcting for possible confounding factors, only Rejuvant produced a statistically significant effect. These findings reinforce my belief, supported by years of personal use of the product, that Rejuvant can effectively and meaningfully reduce biological age.”
“While many nutraceuticals generate more enthusiasm than meaningful geroscience-based evidence, Rejuvant at least has a plausible mechanism of action and supportive preclinical data,” said Dr. Nir Barzilai, Director of the Institute for Aging Research and Professor of Medicine at the Albert Einstein College of Medicine. “Additionally, post-market experience with use, safety, and user satisfaction is more reassuring compared to many other supplements. In today’s longevity market, this may not be a gold standard, but it’s about as close to an adult in the room as you can get.”